Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference
26.5.2022 15:00:00 EEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced the company is attending the American Society for Mass Spectrometry (ASMS) Annual Conference from June 5 to June 9 in Minneapolis (Minnesota, USA) where the company will launch Spectronaut 16 and present major scientific and technological advances of its proprietary proteomics research services.
Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration. In addition, their team of scientific experts will be present at booth #306 to answer questions and demo software.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly for proteomics data analysis and drug and biomarker discovery.
“Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys. "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.”
Spectronaut 16 provides the deepest proteome coverage available
At this year’s ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars. The first seminar, “Spectronaut 16: Reaching New Depths in DIA Proteomics with AI”, takes place on June 6 with presentations from Oliver Bernhardt (Biognosys) and guest speaker Birgit Schilling (The Buck Institute). The second seminar, “Spectronaut: The Best Ally for Your Visionary Projects,” on June 8 features guest speakers Jesper V. Olsen (University of Copenhagen) and Yansheng Liu (Yale University School of Medicine).
Further, Biognosys will present three posters, demonstrating the significant improvements in Spectronaut 16 for direct searches on complex DIA data with reduced analysis time, deep-learning-based scoring in a dia-PASEF analysis pipeline, and score identifications with minimal computation time through the neural network DeepXIC that uses ion chromatograms to score for identifications.
Biofluid biomarker discovery in neurodegenerative and chronic autoimmune diseases with TrueDiscovery
Biofluids can often be collected less invasively and more frequently than tissue samples to provide an overview of what is happening in the organism. At ASMS, Biognosys will highlight the clinical utility of its proprietary proteomics platform TrueDiscovery™ for unbiased biomarker discovery in biofluids in two oral presentations on June 6. The first oral presentation explores proteomics data collected from CSF and plasma samples in a clinical study in collaboration with Johns Hopkins University, aimed at detecting actionable biomarkers for Alzheimer’s disease (AD). The study identified several proteomic biomarkers for healthy and pathological individuals, some of which were shared in both sample types. The second talk will show data from a clinical study in collaboration with Takeda on Systemic Lupus Erythematosus (SLE). Novel as well as previously reported biomarkers have been identified in plasma and could be used to stratify the disease state. Moreover, disease-specific biomarkers could be described to differentiate patients with renal involvement.
Drug target identification in oncology with TrueTarget
In a collaboration between Biognosys, AstraZeneca, and Pelago Bioscience, proteomics was used to identify and characterize the protein targets of a kinase inhibitor compound across the CDK family. At ASMS, Biognosys will present data demonstrating the performance of its proprietary TrueTarget platform to reveal the target and binding affinity of the drug and highlight complementarities with two other proteomics-based techniques. The presentation builds further on earlier data from this study, published in ACS Chemical Biology.
Visit biognosys.com/asms2022 for a complete overview of Biognosys’ presence at ASMS.
About Spectronaut®
Spectronaut is Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.
The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit spectronaut.com.
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced patented Data Independent Acquisition (DIA)-based protein quantification technology co-invented by tech pioneers at Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
About TrueTarget™
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.
The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005037/en/
Contact information
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects17.11.2026 14:01:00 EET | Press release
Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost
Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google17.11.2026 13:50:00 EET | Press release
Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that Google has signed a power purchase agreement (PPA) for 50 megawatts (MW) of superhot geothermal power from Project Obsidian, Quaise’s flagship project in Central Oregon. Once online, this always-on, carbon-free energy is slated to support Google’s existing data center operations in The Dalles, Ore. and the region’s communities. The agreement will help catalyze the commercial development of superhot geothermal energy, providing benefits for ratepayers and helping protect the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117923219/en/ Beginning as early as 2030, Google will purchase 50 MW of power from Project Obsidian. The initial phase of development will use conventional drilling technology to access superhot geothermal conditions at commercial scale. Superhot geothermal is a virtually limitless energy sourc
Nowhere to Sit, Nothing to Do: Europe’s Biggest Airports Fall Short for Passengers17.11.2026 13:24:00 EET | Press release
One in four of Europe’s 50 biggest airports scores below the global average on all four parts of the experience passengers rated, according to AirHelp data covering 279 airports worldwide. Passengers rated each airport on wait times, restaurants, seating and entertainment. Twelve airports, including Dublin, Manchester, Lisbon, London Luton and Milan Bergamo, came in below the global average on all four. Only four beat all four averages: Zurich, Warsaw, Naples and Ankara. Entertainment is the weak spot almost everywhere Entertainment was the lowest-rated part of the experience at 45 of the 50 airports, averaging 6.5 out of 10, with more than half of the airports falling below the global average of 6.7. Seven airports scored less than 6, including Manchester, Stansted, Dublin and Oslo. The data also suggests that passengers who can’t find a seat usually have nothing to do either: 22 of the 50 airports score below the global average for both seating and entertainment. Many airports offer
Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 11:00:00 EET | Press release
Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, delivery updates and appointment reminders. Instead of developing and maintaining individual messaging integrations,
Luminor Partners With Plumery to Accelerate Delivery of Digital Banking Solutions17.11.2026 10:55:00 EET | Press release
Luminor has partnered with financial technology company Plumery, using its headless digital platform to accelerate the delivery of selected digital banking solutions across Estonia, Latvia and Lithuania. Plumery was selected because its technology and approach align well with Luminor’s strategy. The cooperation forms part of Luminor’s broader work to modernise its technology, simplify its products and strengthen its digital channels. Under the partnership, Luminor uses Plumery’s headless, API-first architecture to design and deliver digital banking experiences in combination with the bank’s own applications, customer journeys and integrations. This allows Luminor to develop and introduce new functionality more efficiently, while retaining control over how its digital services are designed and integrated. Luminor Bloom, hosted on Luminor’s new cloud-based banking platform, is the first solution delivered through the partnership. Plumery provides the digital banking interface used for Lu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
